FDA Peptide Interim Access Policy Goes to White House

FDA Sends Peptide Interim Access Policy to the White House: What We Know

By Medical Team of Generic Peptides

Quick answer. On October 14, 2026, the FDA submitted a document titled "Interim Access Policy for Compounding Using Certain Peptides" to the White House Office of Management and Budget for review [1]. The text has not been published. News reports say the policy would let the FDA use enforcement discretion so that pharmacies could compound some peptides, reportedly including BPC-157, while formal rulemaking continues [4, 5]. As of October 22, 2026, the policy has not been issued, and no peptide has been added to the FDA's 503A bulks list.

What Was Submitted

The federal government's regulatory review site, reginfo.gov, lists a new FDA action under review [1]:

Before most significant federal actions are published, they pass through the Office of Information and Regulatory Affairs (OIRA), part of OMB. A listing at OIRA confirms that a document exists and is under review. It does not show the document's content, and it does not guarantee when — or in what form — the policy will appear.

What Is Confirmed and What Is Only Reported

Because the text is not public, it helps to separate the facts from the reporting.

Confirmed:

• The FDA submitted the policy to OMB on October 14, 2026, under the title above [1].
• It is classified as a notice, not a proposed or final rule [1].
• The Alliance for Pharmacy Compounding called the submission "potentially significant" but said its contents and release date are still unclear [2].

Reported, not yet confirmed by a published document:

• That the policy would rely on enforcement discretion — meaning the FDA would not act against qualifying pharmacies that compound certain peptides — rather than formally adding them to the 503A bulks list [4, 5].
• That BPC-157 would be among the peptides covered [4, 5].
• That the measure is temporary and meant to bridge the gap until formal rulemaking, which could take years [4].

Legal analysts at two law firms make the same point: the title alone does not tell us which peptides are covered, under what conditions, or whether the policy applies only to 503A compounding pharmacies [3, 6].

How We Got Here

The interim policy is the latest step in a year of fast-moving peptide regulation. Our earlier coverage of the July 2026 FDA peptide meeting explains the background in detail. In short:

PCAC votes are advisory. Adding a substance to the 503A bulks list requires rulemaking, and no peptide has yet completed that process [3]. A second PCAC meeting is expected before the end of February 2027, with no date set [3].

What the Policy Would and Would Not Do

Based on what has been reported, an interim access policy would be an enforcement approach, not an approval.

It would not:

• Approve any peptide as safe or effective. Kennedy himself acknowledged in his October 20 interview that the FDA has not approved these peptides as safe or effective [5].
• Change the law or formally add peptides to the 503A bulks list [6].
• Turn advisory committee votes into a final decision.

It might:

• Allow licensed compounding pharmacies to prepare certain peptides for prescriptions without FDA enforcement action, under conditions the agency would set.
• Serve as a bridge similar to other interim FDA compounding policies already in place [6].

Analysts at Holland & Knight expect the policy, if issued, to apply to licensed 503A pharmacies, and not to research-use-only, supplement or 503B outsourcing channels [3]. That is their assessment, not confirmed text.

Criticism and Open Questions

The plan is contested. The Center for Science in the Public Interest urged the FDA to disregard the advisory committee's recommendations, noting that some committee members have ties to peptide businesses and that FDA scientists had raised safety concerns [5]. The FDA's own staff briefing documents in June recommended against all seven peptides on the agenda [3].

The key open questions are:

• Which peptides are covered? Reports name BPC-157; whether the policy covers all six PCAC-recommended peptides is unknown.
• What conditions apply? For example, limits on routes, sources of bulk material, or documentation.
• When will it be released? A4PC notes reports of a large backlog of HHS actions at OMB, which could affect timing [2].
• How long will it last? Holland & Knight expects a permanent federal pathway more likely in 2027–2028, through proposed and final rules after the next PCAC meeting [3].

What This Means for Researchers

For laboratories and researchers, the practical message is simple: nothing has changed yet. The policy concerns compounding by licensed pharmacies for patients, which is a separate channel from research materials. None of the peptides involved is FDA-approved, and the scientific evidence behind them — mostly animal studies and small human trials — is the same as before the submission.

What does matter is documentation. Regulators, journalists and buyers are paying closer attention to how peptides are made and tested. A lot-specific certificate of analysis with mass spectrometry and HPLC data is the simplest way to show what is in a vial. Our guide on how to read a research peptide COA explains what each section should contain. Generic Peptides publishes a lot-specific COA for each batch of research-grade BPC-157, TB-500, Semax and Epitalon — four of the six peptides the PCAC recommended.

For peptide-by-peptide background, see our post-PCAC reviews of BPC-157, TB-500, Semax, Epitalon, KPV and MOTS-c. We will update this article when the policy text is published.

FAQ

What is the FDA's interim access policy for peptides?

It is a document titled "Interim Access Policy for Compounding Using Certain Peptides" that the FDA submitted to the White House Office of Management and Budget on October 14, 2026. Its text has not been published.

Does this mean BPC-157 is FDA approved?

No. Reports say the policy may allow pharmacies to compound BPC-157 under enforcement discretion, but that is not approval. BPC-157 is not an FDA-approved drug.

Has any peptide been added to the 503A bulks list?

Not as of October 22, 2026. The July 2026 PCAC votes were advisory, and adding a substance to the list requires rulemaking.

When will the policy be released?

No date has been announced. The policy is listed as pending review at OMB, and there is no legal deadline.

Does the policy affect research-use peptides?

Based on reports, it concerns compounding by licensed pharmacies. Legal analysts expect it not to cover research-use-only channels, but the text has not been published.

References

For research use only. Not for human consumption. This content is for informational purposes and is not medical advice.